Conversion of Nightingale Health Plc’s Series A shares to Series B shares

HEALTHRegulatory press release2026-09-28 11:56

Nightingale Health Plc | Stock Exchange Release | September 28, 2026 at 12:56:00 EEST

The Board of Directors of Nightingale Health Plc (“Nightingale Health”) has in its meeting on 1 September 2026 approved request of shareholders to convert 112,600 Series A shares to Series B shares in accordance with Article 5 in the Articles of Association.

As a result of conversion of shares, the number of the Nightingale Health’s Series A shares is 19,262,168, Series B shares is 40,647,779, and EMP shares is 1,028,968. The conversion does not affect the total amount of shares which is 60,938,915. After the conversion, the number of votes of Nightingale Health’s shares is 233,269,459.

The conversions of shares were registered in the Trade Register on 28 September 2026. The converted shares will be listed on the regulated market of Nasdaq Helsinki together with the old shares as of 29 September 2026.

About Nightingale Health
Chronic diseases cause around 75% of deaths globally and place a growing burden on healthcare systems. The way to address this is preventive healthcare, but until recently the tools to detect disease risks at population scale have not existed. Nightingale Health has built them. The Nightingale Health Check is a blood-based risk detection test that identifies risks for multiple chronic diseases, including cardiovascular disease, type 2 diabetes, kidney disease, and fatty liver disease, from a single blood sample. It is designed to be applied population-wide, so healthcare systems can identify the people who would benefit most from preventive action before disease develops.

Nightingale Health's technology is validated in over 1,000 peer-reviewed scientific publications and is used in many of the world's leading health studies, including the UK Biobank. In Finland, the Nightingale Health Check is in nationwide healthcare use, and over 250,000 people have already received their results. Nightingale Health operates globally with a parent company in Finland and subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom, and has customers in more than 34 countries across healthcare and medical research. The company's Series B shares are listed on the Main Market of Nasdaq Helsinki and on the OTCQX International market. Read more: https://nightingalehealth.com/